Study Of 323U66 SR In Major Depressive Disorder

• Status: Completed
• Trial end date: 2007-05-28
• Target enrollment: 0
• Participant gender: All

Summary

This study was designed to evaluate the efficacy and safety in major depressive disorder patients.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: GlaxoSmithKline
• Treatments: Bupropion

Criteria

Inclusion criteria:

• Met DSM-IV-TR criteria for major depressive disorder for their current episode for at least 8 weeks prior to screening visit.

• Must give a written informed consent. But if the patient is under 20, both the patient himself/herself and his/her proxy consenter must give written informed consent.

• Must have rating scores as outlined.

Exclusion criteria:

• Current or past history of seizure disorder or brain injury.

• Current or past history of anorexia or bulimia nervosa.

• History of manic episode.

• Past or current DSM- IV-TR diagnosis of schizophrenia or other psychotic disorder.

• Diagnosis of substance abuse (alcohol or drug) by the DSM-IV-TR criteria.

• Pregnant, possibly pregnant or lactating.

• Must not be suicidal.

• Blood pressure of SBP>160mmHg, DBP>100mmHg.

• History or complication of cancer or malignant tumour.